July 1, 2019 (Future Science)
While early diagnosis and availability of various therapies are crucial to for improved outcomes for patients with breast cancer, unfortunately, patients diagnosed with triple-negative breast cancer (TNBC) only have a few available treatment options to try and combat the disease.
A study set out to investigate two previously developed antibodies that bind to perlecan, a cell surface protein, that is overexpressed in TNBC.
Upon application of various methods, results showed that the antibodies were “covalently conjugated to nanoparticles without affecting antibody binding affinity or nanoparticle properties.” Furthermore, conclusions drawn from the data indicate that perlecan-targeted nanoparticles can improve tumor drug delivery to TNBC.